Law360 -- Michigan-based retailer Meijer Inc. on Tuesday launched a putative class action in Massachusetts federal court accusing Ranbaxy Inc. of recklessly stuffing generic drug approval queues with deceptive applications in an effort to block or delay competitors from coming to market.
Steve Shadowen argues on behalf of plaintiffs before Third Circuit Court of Appeals in chocolate price fixing case.
Steve Shadowen served as a panel member at an event put together by the American Bar Association's Section on Antitrust law, discussing how antitrust courts should address cases challenging product hopping practices.
The American Antitrust Institute elected Steve Shadowen to be one of its presenters at a symposium aimed at exploring the implications and applications of antitrust law in the wake of the landmark U.S. Supreme Court decision in FTC v. Actavis, Inc.
Plaintiffs pursuing class actions against AbbVie Inc. and Teva Pharmaceuticals Industries Ltd. over allegedly improper pay-for-delay settlements aimed at barring generic versions of the cholesterol drug Niaspan from entering the market have failed to show they were injured by the deal, a Pennsylvania federal judge heard Tuesday.
“They are trying to require us to plead evidence,” Shadowen said. “Our allegations after discovery and depositions are going to be more fulsome than they are now, no doubt about it. But that's not the standard.”
WASHINGTON DC - December 3, 2013 - The American Antitrust Institute (AAI) held its first annual Antitrust Enforcement Awards tonight, honoring litigation achievements in economics and private law practice.